I would like to take this opportunity to outline the details of a significant milestone for NanoSphere Health Sciences and how this will impact the future of the company. We have been granted our landmark patent for the NanoSphere Delivery System™, which means we now officially have ownership of the biggest advancement in non-invasive medical delivery in over 25 years. A major thank you is in order to everyone who has come on this journey with us, especially those who have been here since the very beginning—from the challenging years of R&D through the pivotal point of commercialization to now, as we realize this new reality and lay the foundation for the bright future of this business.
Landmark patent marks most significant advancement in over 25 years for non-invasive medical delivery system
Denver (March 27, 2018) – NanoSphere Health Sciences Inc (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.
CannabisTech had the opportunity to speak with David Sutton, the President and Chief Operating Officer of NanoSphere Health Sciences about their new product Evolve Nanoserum and the technology which made it possible.
CFN sat down with NanoSphere Health Sciences COO David Sutton at the recent Seed to Sale show in Denver Colorado.
As research into cannabis has grown, the demand for new and innovative delivery methods has exploded. NanoSphere Health Sciences (NSHS.CN) (CSE:NSHS) (CNSX: NSHS) is disrupting the space through its innovative delivery systems,